QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 trevi-therapeutics-inc-files-for-mixed-shelf-size-not-disclosed-says-in-addition-offering-of-up-to-200m-of-common-stock

-SEC Filing

 trevi-therapeutics-q3-eps-008-beats-010-estimate

Trevi Therapeutics (NASDAQ:TRVI) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(...

 morgan-stanley-initiates-coverage-on-trevi-therapeutics-with-overweight-rating-announces-price-target-of-18

Morgan Stanley analyst Judah Frommer initiates coverage on Trevi Therapeutics (NASDAQ:TRVI) with a Overweight rating and ann...

 lisa-delfini-to-resign-as-cfo-of-trevi-therapeutics-on-aug-22--jennifer-l-good-to-serve-as-interim-principal-financial-officer

-SEC Filing

 raymond-james-maintains-strong-buy-on-trevi-therapeutics-lowers-price-target-to-27

Raymond James analyst Ryan Deschner maintains Trevi Therapeutics (NASDAQ:TRVI) with a Strong Buy and lowers the price target...

 needham-maintains-buy-on-trevi-therapeutics-lowers-price-target-to-22

Needham analyst Serge Belanger maintains Trevi Therapeutics (NASDAQ:TRVI) with a Buy and lowers the price target from $24 to...

 trevi-therapeutics-q2-eps-009-beats-010-estimate

Trevi Therapeutics (NASDAQ:TRVI) reported quarterly losses of $(0.09) per share which beat the analyst consensus estimate of $(...

 cantor-fitzgerald-initiates-coverage-on-trevi-therapeutics-with-overweight-rating-announces-price-target-of-25

Cantor Fitzgerald analyst Josh Schimmer initiates coverage on Trevi Therapeutics (NASDAQ:TRVI) with a Overweight rating and ...

 trevi-therapeutics-launches-100m-public-offering-of-common-stock-to-support-development-of-haduvio-for-chronic-cough-in-ipf-and-rcc

Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduv...

 trevi-therapeutics-showcases-drug-that-cuts-cough-frequency-in-lung-disease-patients

Trevi's Haduvio met its primary endpoint in a Phase 2b trial for IPF-related chronic cough, with statistically significant ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION